Pharmaceuticals company Caplin Point Laboratories announced Q2FY27 results Consolidated Financial Highlights: Revenue from Operations: Consolidated revenue from operations in Q2FY27 stood at Rs 629.84 crore, reflecting a QoQ growth of 3.19% from Rs 610.36 crore in Q1FY27 and a YoY growth of 17.94% from Rs 534.04 crore in Q2FY26. For H1FY27, consolidated revenue from operations reached Rs 1,240.20 crore, up 18.76% YoY from Rs 1,044.26 crore in H1FY26. Total Income: Consolidated total income in Q2FY27 stood at Rs 663.13 crore, increasing by 2.98% QoQ from Rs 643.91 crore in Q1FY27 and by 17.49% YoY from Rs 564.41 crore in Q2FY26. For H1FY27, consolidated total income reached Rs 1,307.04 crore, growing 19.06% YoY from Rs 1,097.77 crore in H1FY26. Profit Before Tax (PBT): Consolidated PBT in Q2FY27 stood at Rs 232.83 crore, up 3.38% QoQ from Rs 225.22 crore in Q1FY27 and 15.84% YoY from Rs 201.00 crore in Q2FY26. For H1FY27, consolidated PBT was Rs 458.05 crore, representing a YoY increase of 18.83% over Rs 385.46 crore in H1FY26. Profit After Tax (PAT): Consolidated PAT in Q2FY27 stood at Rs 182.35 crore, rising by 1.82% QoQ from Rs 179.09 crore in Q1FY27 and 13.81% YoY from Rs 160.23 crore in Q2FY26. For H1FY27, consolidated PAT reached Rs 361.44 crore, up 16.22% YoY from Rs 310.99 crore in H1FY26. Earnings Per Share (EPS): Consolidated Basic EPS in Q2FY27 was Rs 23.44, growing 0.73% QoQ from Rs 23.27 in Q1FY27 and 15.35% YoY from Rs 20.32 in Q2FY26, while H1FY27 Basic EPS increased 15.56% YoY to Rs 46.71 from Rs 40.42 in H1FY26. Standalone Financial Highlights: Revenue from Operations: Standalone revenue from operations in Q2FY27 stood at Rs 241.88 crore, growing 19.18% QoQ from Rs 202.95 crore in Q1FY27 and 38.08% YoY from Rs 175.18 crore in Q2FY26. For H1FY27, standalone revenue from operations reached Rs 444.83 crore, up 24.34% YoY from Rs 357.75 crore in H1FY26. Total Income: Standalone total income in Q2FY27 stood at Rs 292.92 crore, increasing by 10.23% QoQ from Rs 265.74 crore in Q1FY27 and 24.97% YoY from Rs 234.40 crore in Q2FY26. For H1FY27, standalone total income reached Rs 558.66 crore, marking a YoY growth of 24.42% from Rs 449.00 crore in H1FY26. Profit Before Tax (PBT): Standalone PBT in Q2FY27 stood at Rs 167.05 crore, up 10.93% QoQ from Rs 150.59 crore in Q1FY27 and 29.50% YoY from Rs 129.00 crore in Q2FY26. For H1FY27, standalone PBT rose 31.55% YoY to Rs 317.64 crore from Rs 241.46 crore in H1FY26. Profit After Tax (PAT): Standalone PAT in Q2FY27 stood at Rs 130.51 crore, increasing by 8.42% QoQ from Rs 120.38 crore in Q1FY27 and 27.22% YoY from Rs 102.59 crore in Q2FY26. For H1FY27, standalone PAT reached Rs 250.89 crore, up 33.11% YoY from Rs 188.48 crore in H1FY26. Earnings Per Share (EPS): Standalone Basic EPS in Q2FY27 was Rs 17.17, up 8.40% QoQ from Rs 15.84 in Q1FY27 and 27.19% YoY from Rs 13.50 in Q2FY26, while H1FY27 Basic EPS grew 33.10% YoY to Rs 33.01 from Rs 24.80 in H1FY26. Business Highlights & Segment-Wise Performance: Rest of the World (RoW): Segment revenue in Q2FY27 was Rs 500.12 crore, up 5.05% QoQ from Rs 476.07 crore in Q1FY27 and 17.10% YoY from Rs 427.08 crore in Q2FY26, while H1FY27 revenue grew 17.53% YoY to Rs 976.19 crore from Rs 830.61 crore in H1FY26. United States of America (USA): Segment revenue in Q2FY27 was Rs 129.72 crore, down 3.40% QoQ from Rs 134.29 crore in Q1FY27 but up 21.28% YoY from Rs 106.96 crore in Q2FY26, while H1FY27 revenue increased 23.57% YoY to Rs 264.01 crore from Rs 213.65 crore in H1FY26. Geographical Revenue Mix: Emerging Markets (Latin America and Africa): and the US accounted for 79% and 21% of H1FY27 revenue, respectively. C.C. Paarthipan, Chairman, said: “H1FY27 has been another half of disciplined, broad-based growth for Caplin Point. Total revenue crossed Rs 1,300 crore and EBITDA crossed Rs 500 crore, both up close to 20% YoY, and our margins have held firm. Our Latin American business keeps getting stronger: we won new tenders in Central America and Chile, started oncology sales in Mexico, and have a strong R&D; pipeline that positions us well in one of our high target growth markets. In the US, Caplin Steriles USA has surpassed its full FY26 sales in just the first six months of its second full year, which shows how quickly our own-label business is winning customers. We are reinvesting what we earn into new capacity and capabilities, including oncology, APIs, the COL-II facility, pre-filled syringes and digitalisation. With free cash reserves of Rs 1,534 crore, we have the balance sheet to fund this expansion from a position of strength. I thank our employees, partners and shareholders for their continued trust as we build a more integrated and more global Caplin Point.” Result PDF